AzTrials
AzTrials

Functional ConstipationPhase 4NCT01622972

Mode of Action of Moviprep

A Phase 4 study testing Polyethyleneglycol in people with Functional Constipation and Irritable Bowel Syndrome Characterized by Constipation, run by University of Nottingham at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The University of Nottingham have been developing new, non-invasive magnetic resonance imaging (MRI) techniques to image the bowel. Building on those studies the investigators want to study, in healthy volunteers, the effects of purging on the colon. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
What is being tested?
Polyethyleneglycol
Could I receive a placebo?
No, everyone receives an active treatment
How many people
72 participants
Where
1 siteUnited Kingdom
Study dates
Sep 2011to Feb 2014
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Male or female healthy volunteers who are 18-65 years
  • BMI 18-28 kg/m2
  • Able to give voluntary written informed consent to participate in the study
  • Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures
  • Male or female who are 18-65 years
  • BMI 18-30 kg/m2
Show all 10Show fewer
  • Able to give voluntary written informed consent to participate in the study
  • Able to understand the requirements of the study, including anonymous publication, and agree to co-operate with the study procedures
  • Patient diagnosed with constipation predominant irritable bowel syndrome who failed to respond to at least 1 laxative treatment in the past
  • Patient diagnosed with functional constipation who failed to respond to 1-2 sachets of Movicol per day

Who cannot join

  • Any history of serious acute or chronic illness especially gastrointestinal
  • Diabetes Mellitus
  • Pregnancy or breast feeding
  • Smoking
  • Unsuitable for MRI scanning (i.e. have metal implants or a pace maker)
  • Regular use of medication interfering with gastrointestinal function including opiates or constipating drugs
Show all 19Show fewer
  • Subjects using the oral contraceptive pill will be excluded if not prepared to use an alternative barrier method of contraception for the duration of the menstrual cycle following dosing with Moviprep
  • Substance abuse
  • Have taken part in another clinical study within the previous 3 months
  • Previous gastrointestinal surgery of any kind apart from appendicectomy
  • Any history of serious acute or chronic illness especially gastrointestinal
  • Diabetes Mellitus
  • Pregnancy or breast feeding
  • Unsuitable for MRI scanning (i.e. have metal implants or a pace maker)
  • Regular use of medication interfering with gastrointestinal function including opiates or constipating drugs
  • Subjects using the oral contraceptive pill will be excluded if not prepared to use an alternative barrier method of contraception for the duration of the menstrual cycle following dosing with Moviprep
  • Substance abuse
  • Have taken part in another clinical study within the previous 3 months
  • Previous gastrointestinal surgery of any kind apart from appendicectomy/cholecystectomy

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Nottingham Digestive Diseases Centre, University of Nottingham

    Nottingham, NG7 2UH

Other trials in United Kingdom

About this study

Official title: Mode of Action of Moviprep:Impact on Distribution of Intestinal Fluid and Colonic Microbiota

The University of Nottingham have been developing new, non-invasive magnetic resonance imaging (MRI) techniques to image the bowel. Building on those studies the investigators want to study, in healthy volunteers, the effects of purging on the colon. The investigators plan two studies using their novel MRI techniques in healthy volunteers to demonstrate how doses of a preparation designed to clean the bowel alters small and large bowel water content and transit. The investigators will also define the changes induced in colonic microbiota and how these are linked to changes in transit and the structure of colonic contents. This experimental model is comparable to an episode of acute diarrhea, therefore this study will also improve their understanding of the effects of diarrhea on bowel physiology.

Following from the above study, the investigators would like to extend this study on patients who have functional constipation and previously have not responded to conventional laxatives.

Read the detailed description

Routine examinations of the colon including colonoscopy and barium enema widely carried out in clinical practice require evacuation of colonic contents. This is most conveniently carried out using osmotic laxatives the most widely used preparation being based on polyethylene glycol such as Moviprep. When fully made up as 1 litre of Moviprep , it provides 100 grams of polyethlene glycol '3350' with a measured osmolarity of around 530 mosmol/l. Being nonnutrient, this would be expected to rapidly leave the stomach and generate a substantial inflow of fluid in the upper small intestine as water flows down the osmotic gradient markedly increasing the small intestinal water content compared with fasting.

Previous MRI studies using a Mannitol solution of 300 mosmols/l resulted in a small bowel secretion of fluid increasing total small bowel water to nearly 400 mls after a 300 ml meal. The investigators would anticipate a much larger increase after the hypertonic Moviprep. The flush of small bowel fluid induced by mannitol produces a radical change in the heterogeneous structure of the ascending colon as shown in our recent MRI images of the colon before and after mannitol.

Contrary to expectation colonic contents are far from homogenous with a spatially organised bacterial flora which others have described at a microscopic level which the investigators are just beginning to demonstrate using their novel MRI techniques. The colon should be regarded as a complex bioreactor which is spatially highly organised with a mucous layer overlying the enterocytes, the outer layer of mucus containing a germinal layer with bacteria which reseed the bioreactor when it is purged. The rate of recovery after purgation with polyethylene glycol is said to be normally rapid as the intact germinal layer rapidly recolonises but slower in certain patient groups though data is very limited as yet. The anecdotal yet persuasive patient accounts of improvement in bowel function after colonic lavage suggest that the reconstituted microbiota may be different, though this has yet to be studied using modern techniques.

Until recently the investigators have had no way of noninvasive imaging this complex structure but recent developments of high resolution MRI in Nottingham show that this is now feasible. Pilot data demonstrates that purging removes the heterogeneous three dimensional structure leaving homogeneous fluid contents with an intense proton signal. Just how this impacts on the colonic microbiota is as yet unknown as there have been no studies to date combining these novel approaches with new techniques now available for assessing the microbiota.

Early culture-based assessments identify only a minority of all the faecal organisms present and it is only in the last decade that methods based on assessment of microbial DNA have evolved to make it possible to describe the full complexity of the faecal microbiota. PCR of the highly conserved 16s ribosomal RNA gene shows the microbiota of individuals to be highly complex and individualised. Similarity indices show similarities of around two thirds over a 7 week period in healthy controls while those developing acute diarrhoea due to radiation enteritis show a marked reduction to just 26%. Similarly, HITChip analysis showed that subjects with IBS had an unstable microbiota that was stabilised following a probiotic intervention trial that improved the IBS symptom score. These techniques have yet to be applied to subjects undergoing bowel purgation. Moreover, there are novel approaches to identify the viability of the microbiota such as the use of specific probes that allow discrimination between intact, damaged and dead cells in fecal samples.

Being tested
Polyethyleneglycol

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PolyethyleneglycolDrug

    Also called Macrogol 3350, Moviprep

    Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.

Study groups in NCT01622972
Study groupRoleWhat they receive
Group 1ExperimentalHealthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
Receives: Drug: Polyethyleneglycol
Group 2ExperimentalHealthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
Receives: Drug: Polyethyleneglycol
Group 3ExperimentalPatients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
Receives: Drug: Polyethyleneglycol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Effect of 1 or 2 litre of Moviprep on area under curve (AUC) small bowel water content 0-6 hours on healthy volunteers

    Healthy Volunteers

    Measured: up to 24 hours

  2. To assess area under curve of small bowel water content following 1litre of Moviprep on patients with constipation

    Patients with constipation

    Measured: up to 6 hours

Secondary outcomes (12)
  1. Effect of 2 different dosing regimens of Moviprep on cleansing of the colon as assessed from colonic contents on the last scan at the end of purgation

    Healthy volunteers

    Measured: up to 24 hours

  2. Effect of 2 different dosing regimens of Moviprep on the time course of the intestinal water content

    Healthy volunteers

    Measured: 6 weeks

  3. Effect of 2 different dosing regimens of Moviprep on the time course of the ascending colon total chyme volume

    healthy volunteers

    Measured: 6 weeks

  4. Effect of 2 different dosing regimens of Moviprep on the time course of the Colonic motility index 'cine' MRI movies

    Healthy volunteers

    Measured: 6 weeks

  5. Effect of 2 different dosing regimens of Moviprep on the time course of the transit assessment from mean position of marker capsules

    Healthy volunteers

    Measured: 6 weeks

  6. Comparison of single dose versus split dose on above MRI parameters

    healthy volunteers

    Measured: 6 weeks

  7. Rate of recovery of normal colonic microbiota over days 2-28 assessed by bacterial DNA data (HITChip) and SCFA concentration

    healthy volunteers

    Measured: 6 weeks

  8. Correlation between microbiota, SCFA and colonic MRI parameters

    Healthy volunteers

    Measured: 6 weeks

  9. Ascending colon total chime volume

    Patient with constipation

    Measured: up to 6 hours

  10. Colonic motility index 'cine; MRI movies

    Patients with constipation

    Measured: up to 6 hours

  11. C) Comparison of the cross sectional area of the ascending colon with the cross sectional area of the transverse and descending colon

    Patients with constipation

    Measured: up to 6 hours

  12. Transit assessment from mean position of marker capsules at 24 hours

    Patients with constipation

    Measured: 24 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Jun 2012 (estimated)
  2. Study startSep 2011
  3. Primary completionFeb 2014
  4. Study completionFeb 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
72 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01622972
Sponsor's protocol ID
10050
Other IDs
2010-021879-85
Status last verified
Apr 2014
First submitted
15 Jun 2012
Last updated
14 Apr 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Polyethyleneglycol in people with Functional Constipation and Irritable Bowel Syndrome Characterized by Constipation, run by University of Nottingham at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Effect of 1 or 2 litre of Moviprep on area under curve (AUC) small bowel water content 0-6 hours on healthy volunteers (time frame: up to 24 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in